Bar Harbor Trust Services decreased its stake in Johnson & Johnson (NYSE: JNJ – Get Rating) by 0.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 100,400 shares of the company stock after selling 107 shares during the period. Johnson & Johnson makes up 5.4% of Bar Harbor Trust Services’ portfolio, making the stock its biggest position. Bar Harbor Trust Services’ holdings in Johnson & Johnson were worth $ 17,794,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. lifted its stake in shares of Johnson & Johnson by 2.6% in the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company stock worth $ 34,217,654,000 after acquiring an additional 4,982,885 shares in the last quarter. State Street Corp lifted its stake in shares of Johnson & Johnson by 1.8% in the fourth quarter. State Street Corp now owns 144,677,639 shares of the company stock worth $ 24,750,004,000 after acquiring an additional 2,492,359 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Johnson & Johnson by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company stock worth $ 7,576,867,000 after acquiring an additional 1,084,834 shares in the last quarter. Norges Bank acquired a new position in shares of Johnson & Johnson in the fourth quarter worth about $ 4,172,929,000. Finally, Legal & General Group Plc lifted its stake in shares of Johnson & Johnson by 5.8% in the fourth quarter. Legal & General Group Plc now owns 17,420,146 shares of the company stock worth $ 2,980,062,000 after acquiring an additional 948,306 shares in the last quarter. 68.78% of the stock is owned by institutional investors.
In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $ 180.00, for a total transaction of $ 1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares of the company stock, valued at approximately $ 2,785,140. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The shares were sold at an average price of $ 173.00, for a total value of $ 6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company stock, valued at $ 12,336,803. The disclosure for this sale can be found here. Insiders sold a total of 78,161 shares of company stock valued at $ 13,895,302 over the last three months. Corporate insiders own 0.35% of the company stock.
Several analysts have issued reports on JNJ shares. Sanford C. Bernstein cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and upped their price target for the company from $ 180.00 to $ 183.00 in a research note on Wednesday, March 16th. Raymond James upped their price objective on Johnson & Johnson from $ 195.00 to $ 196.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Bank of America started coverage on Johnson & Johnson in a research note on Wednesday, March 2nd. They set a “neutral” rating on the stock. The Goldman Sachs Group upped their price target on Johnson & Johnson from $ 163.00 to $ 181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Finally, Credit Suisse Group upped their price target on Johnson & Johnson from $ 200.00 to $ 205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $ 190.50.
Shares of JNJ stock opened at $ 176.94 on Wednesday. Johnson & Johnson has a 12-month low of $ 155.72 and a 12-month high of $ 186.69. The firm has a market capitalization of $ 465.60 billion, a price-to-earnings ratio of 23.85, a price-to-earnings-growth ratio of 3.61 and a beta of 0.66. The business has a 50 day simple moving average of $ 177.67 and a 200 day simple moving average of $ 173.59. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14.
Johnson & Johnson (NYSE: JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, April 19th. The company reported $ 2.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $ 2.60 by $ 0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The business had revenue of $ 23.43 billion during the quarter, compared to analyst estimates of $ 23.62 billion. During the same period in the prior year, the company posted $ 2.59 EPS. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post 10.23 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were issued a $ 1.13 dividend. This represents a $ 4.52 dividend on an annualized basis and a yield of 2.55%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $ 1.06. The ex-dividend date of this dividend was Monday, May 23rd. Johnson & Johnson’s dividend payout ratio is 60.92%.
Johnson & Johnson Profile: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.